Kerry Regulatory News (KYGA)

26 October 2023

LEI: 635400TLVVBNXLFHWC59

KERRY GROUP PLC

Regulatory Announcement

DIRECTORATE CHANGE

Kerry Group plc ("Kerry") is pleased to announce the appointment of Dr. Genevieve Berger as a non-executive director with effect from 1 November 2023. 

Dr. Berger is a highly accomplished global science leader having served as Director General of one of the world's largest research organisations the Centre National de la Recherche Scientifique (CNRS), and who during her executive career held roles as the Chief Science Officer at Firmenich International SA as well as Chief Research & Development Officer and Chief Science Officer at Unilever plc. Dr Berger holds three doctorates, in addition to being a medical doctor, she holds a PhD in Physics and one in Human Biology.

Dr. Berger is currently a non-executive director of Dassault Systèmes SE (a listed company) and previously served on the Boards of Air Liquide SA, Astra Zeneca plc and Smith & Nephew plc. 

Dr. Berger has confirmed to the Company that, save as disclosed herein, there are no other matters requiring disclosure in respect of Rule 6.1.66 (1) to (6) of the Euronext Dublin Listing Rules and under LR 9.6.13 (1) to (6) of the UK FCA Listing Rules.

Commenting on Dr. Berger's appointment, Kerry Group plc Chairman, Tom Moran said: "We are delighted that Genevieve will be joining our Board. Genevieve brings with her expertise in the areas of human health, nutrition and ingredients which will support Kerry in its future development".